查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1813275

心臟病診斷市場預測（至 2032 年）：按產品、測試類型、生物標記、影像方式、診斷方法、年齡層、應用、最終用戶和地區進行的全球分析

Heart Attack Diagnostics Market Forecasts to 2032 - Global Analysis By Product (Instruments, Consumables, Software, Services), Test Type, Biomarker, Imaging Modality, Diagnosis Method, Age Group, Application, End User, and By Geography
出版日期: | 出版商: Stratistics Market Research Consulting | 英文 200+ Pages | 商品交期: 2-3個工作天內

價格

根據 Stratistics MRC 的數據，全球心臟病診斷市場預計在 2025 年達到 125 億美元，到 2032 年將達到 218 億美元，預測期內的複合年成長率為 8.2%。

心臟病發作診斷是指用於檢測和確認心肌梗塞（心肌梗塞是由心臟血流受限引起的）的醫療程序、檢查和設備。這些診斷包括心臟生物標記血液檢測、心電圖 (ECG)、影像學檢查和壓力測試。它們有助於評估心臟損傷、識別阻塞並確定治療方案。準確及時的心臟病發作診斷對於降低死亡率、改善患者預後以及預防與心臟事件相關的併發症至關重要。

根據《世界心臟報告》，心血管疾病持續影響全球超過5億人。

越來越多採用就地檢驗設備

心臟病診斷市場的成長得益於照護現場(POC) 設備的日益普及，這些設備能夠在床邊或急診室快速準確地檢測心臟生物標記。此類設備顯著縮短了檢測時間，確保及時進行臨床干預並改善患者預後。對分散式醫療保健和緊急應變效率的日益重視，正在推動全球範圍內的普及。此外，可攜式診斷平台的技術進步也促進了即時診斷的普及，使其成為心臟病診斷領域的關鍵驅動力。

農村地區獲得診斷的機會有限

阻礙市場成長的一個重要因素是農村和偏遠地區難以獲得先進的診斷設施。基礎設施缺口、訓練有素的醫務人員缺乏以及高昂的設備成本限制了這些地區採用先進的診斷工具。因此，心臟疾病的延遲診斷會導致治療效果不佳，並擴大醫療保健差距。雖然都市區受益於科技的快速普及，但農村醫療保健系統仍面臨挑戰。這種差距減緩了整體市場滲透率，並限制了公平獲得診斷服務的機會。

整合人工智慧主導的診斷平台

人工智慧 (AI) 與診斷系統的整合為心臟病診斷市場帶來了廣闊的機會。 AI 平台能夠增強對複雜影像和生物標記數據的解讀，從而更快、更準確地檢測心肌梗塞。數位健康和​​預測分析領域不斷成長的投資，支持 AI 在醫院網路中的應用。此外，AI主導的決策支援工具可幫助臨床醫生進行分診和製定治療計劃。隨著 AI 技術的成熟，它們的整合將增強精準診斷，最終徹底改變全球心臟護理路徑。

誤診風險影響臨床信心水平

儘管技術不斷進步，誤診風險仍然是心臟病診斷市場的一大威脅。生物標記檢測和影像檢查中的假陽性和假陰性結果會損害醫生的信心，並對患者安全產生負面影響。這可能導致不必要的治療和介入缺失，從而削弱人們對診斷系統的信心。此外，對不同平台之間測試準確性差異的擔憂進一步加劇了這一威脅。因此，持續的臨床檢驗和標準化對於降低風險和維持診斷信心至關重要。

COVID-19的影響：

新冠疫情嚴重擾亂了心臟病診斷市場，醫院優先考慮新冠治療，並推遲了選擇性心臟檢查。患者不願前往醫療機構就診，進一步減少了診斷量。然而，這場危機加速了就地檢驗和遠端醫療主導的心臟監測解決方案的採用。疫情後的復甦再次強調了早期心臟診斷的重要性，醫療系統也在投資建立具有韌性的診斷基礎設施。因此，新冠疫情既是短期的挫折，也是心臟診斷領域創新和去中心化的長期催化劑。

預計設備部門將成為預測期內最大的部門

由於設備在醫院、診斷實驗室和急救醫療中心的廣泛應用，預計在預測期內將佔據最大的市場佔有率。分析儀、影像設備和生物標記檢測系統等設備構成了心臟診斷的支柱，確保評估的準確性和及時性。對技術先進和自動化診斷設備日益成長的需求進一步鞏固了其主導地位。此外，成像模式和生物標記平台的持續技術創新正在增強設備領域作為市場主要貢獻者的地位。

預測期內，超音波心動圖領域預計將以最高複合年成長率成長

超音波心動圖領域預計將在預測期內實現最高成長率，這得益於其非侵入性特性和提供即時心臟成像的能力。心血管疾病的日益普及以及對超音波診斷的偏好正在推動需求成長。 3D超音波心動圖和可攜式超音波心動圖系統的進步正在提高臨床診斷的準確性和可及性。此外，超音波心動圖在急診和門診環境中已成為快速評估心臟功能的必備工具。技術創新與應用的融合使心臟超音波圖成為成長最快的診斷領域。

比最大的地區

在預測期內，由於患者人數不斷增加、心血管疾病盛行率不斷上升以及醫療基礎設施不斷完善，亞太地區預計將佔據最大的市場佔有率。政府加強早期疾病檢測系統的舉措不斷增多，將進一步推動其應用。此外，在新興經濟體中，經濟高效的診斷解決方案的普及率和可近性也在不斷提高。快速的都市化和生活方式的改變加劇了心臟病風險因素，從而推動了對診斷的需求。這些因素共同使亞太地區成為心臟病診斷的領先區域市場。

複合年成長率最高的地區：

由於先進的醫療基礎設施、高度的診斷意識以及快速的技術應用，北美預計將在預測期內實現最高的複合年成長率。大型診斷公司的強大影響力和大量的研發投入正在加速心臟檢測解決方案的技術創新。優惠的報銷框架正在推動先進診斷技術的市場滲透。此外，對精準診斷和數位健康整合的需求不斷成長，也加速了相關技術的普及。隨著心血管疾病負擔的持續增加，北美正成為成長最快的區域市場。

免費客製化服務

此報告的訂閱者可以使用以下免費自訂選項之一：

  • 公司簡介
    • 全面分析其他市場參與者（最多 3 家公司）
    • 主要企業的SWOT分析（最多3家公司）
  • 區域細分
    • 根據客戶興趣對主要國家進行的市場估計、預測和複合年成長率（註：基於可行性檢查）
  • 競爭基準化分析
    • 根據產品系列、地理分佈和策略聯盟對主要企業基準化分析

目錄

第1章執行摘要

第2章 前言

  • 概述
  • 相關利益者
  • 調查範圍
  • 調查方法
    • 資料探勘
    • 數據分析
    • 數據檢驗
    • 研究途徑
  • 研究材料
    • 主要研究資料
    • 次級研究資訊來源
    • 先決條件

第3章市場走勢分析

  • 驅動程式
  • 抑制因素
  • 機會
  • 威脅
  • 產品分析
  • 應用分析
  • 最終用戶分析
  • 新興市場
  • COVID-19的影響

第4章 波特五力分析

  • 供應商的議價能力
  • 買方的議價能力
  • 替代品的威脅
  • 新進入者的威脅
  • 競爭對手之間的競爭

5. 全球心臟病診斷市場（按產品）

  • 裝置
  • 耗材
  • 軟體
  • 服務

6. 全球心臟病診斷市場（依測試類型）

  • 心電圖（ECG）
  • 血液檢查
  • 心臟超音波圖
  • 冠動脈攝影術

7. 全球心臟病診斷市場（依生物標記）

  • 肌鈣蛋白
  • 肌酸激酶同功酶（CK-MB）
  • 肌紅蛋白
  • C反應蛋白（CRP）
  • 腦鈉肽（BNP）

8. 全球心臟病診斷市場（以影像方式）

  • 心臟超音波圖
  • 電腦斷層掃描（CT）
  • 磁振造影（MRI）
  • 核子造影
  • X光

9. 全球心臟病診斷市場（依診斷方法）

  • 實驗室檢查
  • 影像檢查
  • 就地檢驗

第 10 章。按年齡層別分類的全球心臟病診斷市場

  • 40歲以下
  • 60歲或以上

第 11 章。全球心臟病診斷市場（按應用）

  • 緊急診斷
  • 風險評估
  • 治療監測
  • 調查應用

第 12 章。全球心臟病診斷市場（按最終用戶）

  • 醫院
  • 診斷中心
  • 門診手術中心
  • 研究辦公室

13. 全球心臟病診斷市場（按地區）

  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 德國
    • 英國
    • 義大利
    • 法國
    • 西班牙
    • 其他歐洲國家
  • 亞太地區
    • 日本
    • 中國
    • 印度
    • 澳洲
    • 紐西蘭
    • 韓國
    • 其他亞太地區
  • 南美洲
    • 阿根廷
    • 巴西
    • 智利
    • 其他南美
  • 中東和非洲
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 卡達
    • 南非
    • 其他中東和非洲地區

第14章 重大進展

  • 協議、夥伴關係、合作和合資企業
  • 收購與合併
  • 新產品發布
  • 業務擴展
  • 其他關鍵策略

第 15 章：公司概況

  • Abbott Laboratories
  • Siemens Healthineers
  • F. Hoffmann-La Roche Ltd.
  • GE Healthcare
  • Philips Healthcare
  • Bio-Rad Laboratories Inc.
  • Beckman Coulter（Danaher Corporation）
  • Thermo Fisher Scientific Inc.
  • Qiagen NV
  • Randox Laboratories Ltd.
  • Ortho Clinical Diagnostics
  • Becton, Dickinson and Company（BD）
  • CardioDx Inc.
  • Biomerica Inc.
  • Luminex Corporation
  • BioMerieux SA
  • Nova Biomedical
  • Nihon Kohden Corporation
  • Response Biomedical Corporation
  • Critical Diagnostics
Product Code: SMRC30736

According to Stratistics MRC, the Global Heart Attack Diagnostics Market is accounted for $12.5 billion in 2025 and is expected to reach $21.8 billion by 2032 growing at a CAGR of 8.2% during the forecast period. Heart Attack Diagnostics are medical procedures, tests, and devices used to detect and confirm myocardial infarction, a condition caused by restricted blood flow to the heart. These diagnostics include blood tests for cardiac biomarkers, electrocardiograms (ECG), imaging modalities, and stress tests. They help evaluate heart damage, identify blockages, and guide treatment decisions. Accurate and timely heart attack diagnostics are critical for reducing mortality, improving patient outcomes, and preventing complications related to cardiac events.

According to the World Heart Report, cardiovascular diseases continue to affect more than 500 million people across the globe.

Market Dynamics:

Driver:

Increasing adoption of point-of-care testing devices

The market for heart attack diagnostics is spurred by the rising adoption of point-of-care (POC) testing devices, which enable rapid and accurate detection of cardiac biomarkers at bedside or emergency settings. These devices reduce turnaround times significantly, ensuring timely clinical intervention and improved patient outcomes. Growing emphasis on decentralized healthcare and emergency response efficiency strengthens their adoption globally. Furthermore, technological advancements in portable diagnostic platforms support broader accessibility, making POC testing a pivotal driver in the heart attack diagnostics landscape.

Restraint:

Limited access to diagnostics in rural regions

A significant restraint hindering market growth is the limited access to advanced diagnostic facilities in rural and remote regions. Infrastructure gaps, lack of trained healthcare professionals, and high equipment costs restrict adoption of advanced diagnostic tools in these areas. Consequently, delayed detection of cardiac events leads to poor treatment outcomes, widening healthcare disparities. While urban centers benefit from rapid technological adoption, rural healthcare systems continue to face challenges. This disparity slows overall market penetration and limits equitable diagnostic availability.

Opportunity:

Integration of AI-driven diagnostic platforms

The integration of artificial intelligence (AI) into diagnostic systems presents a promising opportunity for the heart attack diagnostics market. AI-enabled platforms enhance interpretation of complex imaging and biomarker data, enabling faster and more accurate detection of myocardial infarction. Growing investments in digital health and predictive analytics support AI adoption across hospital networks. Additionally, AI-driven decision support tools aid clinicians in triage and treatment planning. As AI technologies mature, their integration enhances precision diagnostics, ultimately revolutionizing cardiac care pathways worldwide.

Threat:

Risk of misdiagnosis affecting clinical trust levels

Despite technological advancements, the risk of misdiagnosis remains a critical threat in the heart attack diagnostics market. False positives or negatives in biomarker assays or imaging tests can undermine physician confidence and negatively impact patient safety. Such occurrences may lead to unnecessary treatments or missed interventions, eroding trust in diagnostic systems. Additionally, concerns over variability in test accuracy across different platforms intensify this threat. Sustained clinical validation and standardization are therefore crucial to mitigate risks and preserve diagnostic credibility.

Covid-19 Impact:

The COVID-19 pandemic significantly disrupted the heart attack diagnostics market, with hospitals prioritizing COVID care and delaying elective cardiac testing. Patient reluctance to visit healthcare facilities further reduced diagnostic volumes. However, the crisis accelerated adoption of point-of-care testing and telehealth-driven cardiac monitoring solutions. Post-pandemic recovery has seen renewed emphasis on early cardiac diagnostics, with healthcare systems investing in resilient diagnostic infrastructure. Consequently, COVID-19 served as both a short-term setback and a long-term catalyst for innovation and decentralization in cardiac diagnostics.

The instruments segment is expected to be the largest during the forecast period

The instruments segment is expected to account for the largest market share during the forecast period, owing to their widespread use in hospitals, diagnostic laboratories, and emergency care centers. Instruments such as analyzers, imaging devices, and biomarker detection systems form the backbone of cardiac diagnostics, ensuring accurate and timely assessments. Growing demand for technologically advanced and automated diagnostic instruments further consolidates their dominance. Moreover, continuous innovation in imaging modalities and biomarker platforms reinforces the instruments segment as the market's leading contributor.

The echocardiogram segment is expected to have the highest CAGR during the forecast period

Over the forecast period, the echocardiogram segment is predicted to witness the highest growth rate, impelled by its non-invasive nature and ability to provide real-time cardiac imaging. The increasing prevalence of cardiovascular diseases and preference for ultrasound-based diagnostics fuel demand. Advancements in 3D and portable echocardiography systems enhance clinical accuracy and accessibility. Additionally, echocardiograms are becoming integral in emergency and outpatient settings for rapid heart function assessment. This convergence of innovation and adoption establishes echocardiography as the fastest-growing diagnostic segment.

Region with largest share:

During the forecast period, the Asia Pacific region is expected to hold the largest market share, driven by its expanding patient pool, rising cardiovascular disease prevalence, and growing healthcare infrastructure. Increasing government initiatives to strengthen early disease detection systems further enhance adoption. Moreover, the presence of cost-effective diagnostic solutions in emerging economies boosts accessibility. Rapid urbanization and lifestyle changes exacerbate cardiac risk factors, fueling diagnostic demand. Collectively, these elements position Asia Pacific as the leading regional market in heart attack diagnostics.

Region with highest CAGR:

Over the forecast period, the North America region is anticipated to exhibit the highest CAGR attributed to advanced healthcare infrastructure, high diagnostic awareness, and rapid technology adoption. Strong presence of leading diagnostic companies and extensive R&D investments accelerate innovation in cardiac testing solutions. Favorable reimbursement frameworks support market penetration of advanced diagnostics. Additionally, growing demand for precision diagnostics and digital health integration amplifies adoption. As cardiovascular burden continues to rise, North America emerges as the fastest-expanding regional market.

Key players in the market

Some of the key players in Heart Attack Diagnostics Market include Abbott Laboratories, Siemens Healthineers, F. Hoffmann-La Roche Ltd., GE Healthcare, Philips Healthcare, Bio-Rad Laboratories, Beckman Coulter (Danaher), Thermo Fisher Scientific Inc., Qiagen N.V., Randox Laboratories, Ortho Clinical Diagnostics, Becton, Dickinson and Company, CardioDx Inc., Biomerica Inc., Luminex Corporation, BioMerieux SA, Nova Biomedical, Nihon Kohden Corporation, Response Biomedical Corporation, and Critical Diagnostics.

Key Developments:

In May 2025, Roche Diagnostics (F. Hoffmann-La Roche Ltd) received FDA 510(k) clearance for an enhanced version of its Elecsys(R) Troponin T high-sensitivity test, aimed at providing even more precise risk stratification for patients presenting with chest pain in the emergency department.

In April 2025, Siemens Healthineers announced the U.S. launch of its Atellica(R) CI1900 Integrated Solution, which combines core laboratory and cardiac testing to deliver a consolidated troponin result from a single platform, improving workflow efficiency for heart attack diagnosis.

In March 2025, Abbott Laboratories initiated a major clinical study across 100 sites in the U.S. and Europe to expand the clinical claims for its Alinity i High-Sensitivity Troponin-I assay, focusing on rapid rule-out protocols to help reduce emergency room overcrowding.

Products Covered:

  • Instruments
  • Consumables
  • Software
  • Services

Test Types Covered:

  • Electrocardiogram (ECG)
  • Blood Tests
  • Echocardiogram
  • Coronary Angiography

Biomarkers Covered:

  • Troponin
  • Creatine Kinase-MB (CK-MB)
  • Myoglobin
  • C-Reactive Protein (CRP)
  • Brain Natriuretic Peptide (BNP)

Imaging Modalities Covered:

  • Echocardiography
  • Computed Tomography (CT)
  • Magnetic Resonance Imaging (MRI)
  • Nuclear Imaging
  • X-ray

Diagnosis Methods Covered:

  • Laboratory Testing
  • Imaging Testing
  • Point-of-Care Testing

Age Groups Covered:

  • Below 40 Years
  • Above 60 Years

Applications Covered:

  • Emergency Diagnosis
  • Risk Assessment
  • Therapy Monitoring
  • Research Applications

End Users Covered:

  • Hospitals
  • Diagnostic Centers
  • Ambulatory Surgical Centers
  • Research Laboratories

Regions Covered:

  • North America
    • US
    • Canada
    • Mexico
  • Europe
    • Germany
    • UK
    • Italy
    • France
    • Spain
    • Rest of Europe
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • New Zealand
    • South Korea
    • Rest of Asia Pacific
  • South America
    • Argentina
    • Brazil
    • Chile
    • Rest of South America
  • Middle East & Africa
    • Saudi Arabia
    • UAE
    • Qatar
    • South Africa
    • Rest of Middle East & Africa

What our report offers:

  • Market share assessments for the regional and country-level segments
  • Strategic recommendations for the new entrants
  • Covers Market data for the years 2024, 2025, 2026, 2028, and 2032
  • Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
  • Strategic recommendations in key business segments based on the market estimations
  • Competitive landscaping mapping the key common trends
  • Company profiling with detailed strategies, financials, and recent developments
  • Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

  • Company Profiling
    • Comprehensive profiling of additional market players (up to 3)
    • SWOT Analysis of key players (up to 3)
  • Regional Segmentation
    • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
  • Competitive Benchmarking
    • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

  • 2.1 Abstract
  • 2.2 Stake Holders
  • 2.3 Research Scope
  • 2.4 Research Methodology
    • 2.4.1 Data Mining
    • 2.4.2 Data Analysis
    • 2.4.3 Data Validation
    • 2.4.4 Research Approach
  • 2.5 Research Sources
    • 2.5.1 Primary Research Sources
    • 2.5.2 Secondary Research Sources
    • 2.5.3 Assumptions

3 Market Trend Analysis

  • 3.1 Introduction
  • 3.2 Drivers
  • 3.3 Restraints
  • 3.4 Opportunities
  • 3.5 Threats
  • 3.6 Product Analysis
  • 3.7 Application Analysis
  • 3.8 End User Analysis
  • 3.9 Emerging Markets
  • 3.10 Impact of Covid-19

4 Porters Five Force Analysis

  • 4.1 Bargaining power of suppliers
  • 4.2 Bargaining power of buyers
  • 4.3 Threat of substitutes
  • 4.4 Threat of new entrants
  • 4.5 Competitive rivalry

5 Global Heart Attack Diagnostics Market, By Product

  • 5.1 Introduction
  • 5.2 Instruments
  • 5.3 Consumables
  • 5.4 Software
  • 5.5 Services

6 Global Heart Attack Diagnostics Market, By Test Type

  • 6.1 Introduction
  • 6.2 Electrocardiogram (ECG)
  • 6.3 Blood Tests
  • 6.4 Echocardiogram
  • 6.5 Coronary Angiography

7 Global Heart Attack Diagnostics Market, By Biomarker

  • 7.1 Introduction
  • 7.2 Troponin
  • 7.3 Creatine Kinase-MB (CK-MB)
  • 7.4 Myoglobin
  • 7.5 C-Reactive Protein (CRP)
  • 7.6 Brain Natriuretic Peptide (BNP)

8 Global Heart Attack Diagnostics Market, By Imaging Modality

  • 8.1 Introduction
  • 8.2 Echocardiography
  • 8.3 Computed Tomography (CT)
  • 8.4 Magnetic Resonance Imaging (MRI)
  • 8.5 Nuclear Imaging
  • 8.6 X-ray

9 Global Heart Attack Diagnostics Market, By Diagnosis Method

  • 9.1 Introduction
  • 9.2 Laboratory Testing
  • 9.3 Imaging Testing
  • 9.4 Point-of-Care Testing

10 Global Heart Attack Diagnostics Market, By Age Group

  • 10.1 Introduction
  • 10.2 Below 40 Years
  • 10.3 Above 60 Years

11 Global Heart Attack Diagnostics Market, By Application

  • 11.1 Introduction
  • 11.2 Emergency Diagnosis
  • 11.3 Risk Assessment
  • 11.4 Therapy Monitoring
  • 11.5 Research Applications

12 Global Heart Attack Diagnostics Market, By End User

  • 12.1 Introduction
  • 12.2 Hospitals
  • 12.3 Diagnostic Centers
  • 12.4 Ambulatory Surgical Centers
  • 12.5 Research Laboratories

13 Global Heart Attack Diagnostics Market, By Geography

  • 13.1 Introduction
  • 13.2 North America
    • 13.2.1 US
    • 13.2.2 Canada
    • 13.2.3 Mexico
  • 13.3 Europe
    • 13.3.1 Germany
    • 13.3.2 UK
    • 13.3.3 Italy
    • 13.3.4 France
    • 13.3.5 Spain
    • 13.3.6 Rest of Europe
  • 13.4 Asia Pacific
    • 13.4.1 Japan
    • 13.4.2 China
    • 13.4.3 India
    • 13.4.4 Australia
    • 13.4.5 New Zealand
    • 13.4.6 South Korea
    • 13.4.7 Rest of Asia Pacific
  • 13.5 South America
    • 13.5.1 Argentina
    • 13.5.2 Brazil
    • 13.5.3 Chile
    • 13.5.4 Rest of South America
  • 13.6 Middle East & Africa
    • 13.6.1 Saudi Arabia
    • 13.6.2 UAE
    • 13.6.3 Qatar
    • 13.6.4 South Africa
    • 13.6.5 Rest of Middle East & Africa

14 Key Developments

  • 14.1 Agreements, Partnerships, Collaborations and Joint Ventures
  • 14.2 Acquisitions & Mergers
  • 14.3 New Product Launch
  • 14.4 Expansions
  • 14.5 Other Key Strategies

15 Company Profiling

  • 15.1 Abbott Laboratories
  • 15.2 Siemens Healthineers
  • 15.3 F. Hoffmann-La Roche Ltd.
  • 15.4 GE Healthcare
  • 15.5 Philips Healthcare
  • 15.6 Bio-Rad Laboratories Inc.
  • 15.7 Beckman Coulter (Danaher Corporation)
  • 15.8 Thermo Fisher Scientific Inc.
  • 15.9 Qiagen N.V.
  • 15.10 Randox Laboratories Ltd.
  • 15.11 Ortho Clinical Diagnostics
  • 15.12 Becton, Dickinson and Company (BD)
  • 15.13 CardioDx Inc.
  • 15.14 Biomerica Inc.
  • 15.15 Luminex Corporation
  • 15.16 BioMerieux SA
  • 15.17 Nova Biomedical
  • 15.18 Nihon Kohden Corporation
  • 15.19 Response Biomedical Corporation
  • 15.20 Critical Diagnostics

List of Tables

  • Table 1 Global Heart Attack Diagnostics Market Outlook, By Region (2024-2032) ($MN)
  • Table 2 Global Heart Attack Diagnostics Market Outlook, By Product (2024-2032) ($MN)
  • Table 3 Global Heart Attack Diagnostics Market Outlook, By Instruments (2024-2032) ($MN)
  • Table 4 Global Heart Attack Diagnostics Market Outlook, By Consumables (2024-2032) ($MN)
  • Table 5 Global Heart Attack Diagnostics Market Outlook, By Software (2024-2032) ($MN)
  • Table 6 Global Heart Attack Diagnostics Market Outlook, By Services (2024-2032) ($MN)
  • Table 7 Global Heart Attack Diagnostics Market Outlook, By Test Type (2024-2032) ($MN)
  • Table 8 Global Heart Attack Diagnostics Market Outlook, By Electrocardiogram (ECG) (2024-2032) ($MN)
  • Table 9 Global Heart Attack Diagnostics Market Outlook, By Blood Tests (2024-2032) ($MN)
  • Table 10 Global Heart Attack Diagnostics Market Outlook, By Echocardiogram (2024-2032) ($MN)
  • Table 11 Global Heart Attack Diagnostics Market Outlook, By Coronary Angiography (2024-2032) ($MN)
  • Table 12 Global Heart Attack Diagnostics Market Outlook, By Biomarker (2024-2032) ($MN)
  • Table 13 Global Heart Attack Diagnostics Market Outlook, By Troponin (2024-2032) ($MN)
  • Table 14 Global Heart Attack Diagnostics Market Outlook, By Creatine Kinase-MB (CK-MB) (2024-2032) ($MN)
  • Table 15 Global Heart Attack Diagnostics Market Outlook, By Myoglobin (2024-2032) ($MN)
  • Table 16 Global Heart Attack Diagnostics Market Outlook, By C-Reactive Protein (CRP) (2024-2032) ($MN)
  • Table 17 Global Heart Attack Diagnostics Market Outlook, By Brain Natriuretic Peptide (BNP) (2024-2032) ($MN)
  • Table 18 Global Heart Attack Diagnostics Market Outlook, By Imaging Modality (2024-2032) ($MN)
  • Table 19 Global Heart Attack Diagnostics Market Outlook, By Echocardiography (2024-2032) ($MN)
  • Table 20 Global Heart Attack Diagnostics Market Outlook, By Computed Tomography (CT) (2024-2032) ($MN)
  • Table 21 Global Heart Attack Diagnostics Market Outlook, By Magnetic Resonance Imaging (MRI) (2024-2032) ($MN)
  • Table 22 Global Heart Attack Diagnostics Market Outlook, By Nuclear Imaging (2024-2032) ($MN)
  • Table 23 Global Heart Attack Diagnostics Market Outlook, By X-ray (2024-2032) ($MN)
  • Table 24 Global Heart Attack Diagnostics Market Outlook, By Diagnosis Method (2024-2032) ($MN)
  • Table 25 Global Heart Attack Diagnostics Market Outlook, By Laboratory Testing (2024-2032) ($MN)
  • Table 26 Global Heart Attack Diagnostics Market Outlook, By Imaging Testing (2024-2032) ($MN)
  • Table 27 Global Heart Attack Diagnostics Market Outlook, By Point-of-Care Testing (2024-2032) ($MN)
  • Table 28 Global Heart Attack Diagnostics Market Outlook, By Age Group (2024-2032) ($MN)
  • Table 29 Global Heart Attack Diagnostics Market Outlook, By Below 40 Years (2024-2032) ($MN)
  • Table 30 Global Heart Attack Diagnostics Market Outlook, By Above 60 Years (2024-2032) ($MN)
  • Table 31 Global Heart Attack Diagnostics Market Outlook, By Application (2024-2032) ($MN)
  • Table 32 Global Heart Attack Diagnostics Market Outlook, By Emergency Diagnosis (2024-2032) ($MN)
  • Table 33 Global Heart Attack Diagnostics Market Outlook, By Risk Assessment (2024-2032) ($MN)
  • Table 34 Global Heart Attack Diagnostics Market Outlook, By Therapy Monitoring (2024-2032) ($MN)
  • Table 35 Global Heart Attack Diagnostics Market Outlook, By Research Applications (2024-2032) ($MN)
  • Table 36 Global Heart Attack Diagnostics Market Outlook, By End User (2024-2032) ($MN)
  • Table 37 Global Heart Attack Diagnostics Market Outlook, By Hospitals (2024-2032) ($MN)
  • Table 38 Global Heart Attack Diagnostics Market Outlook, By Diagnostic Centers (2024-2032) ($MN)
  • Table 39 Global Heart Attack Diagnostics Market Outlook, By Ambulatory Surgical Centers (2024-2032) ($MN)
  • Table 40 Global Heart Attack Diagnostics Market Outlook, By Research Laboratories (2024-2032) ($MN)

Note: Tables for North America, Europe, APAC, South America, and Middle East & Africa Regions are also represented in the same manner as above.